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The role of reactive oxygen species (ROS) and antioxidants in cancer is controversial because of their
context-dependent ability to promote or suppress tumorigenesis. Piskounova et al. (2015) now show that
ROS limit distant metastasis: only cells with increased antioxidant capacity are able to succeed in their pur-
pose to metastasize.Tumor metastasis is the main cause of
death in cancer patients. The acquisition
of specific traits by cancer cells,
including migration, invasion, and sur-
vival in the bloodstream, permits metas-
tasis. Of all the tumor cells that reach
the circulation, only a few are able to
generate metastases in distant organs.
Emerging evidence suggests that oxida-
tive stress acts as a key driver of the
malignant transformation observed in pri-
mary tumors that enhances their meta-
static potential. In a recent Nature paper,
Piskounova et al. show that increased
production of reactive oxygen species
(ROS) is essential to enable and sustain
a highly metastatic phenotype (Piskou-
nova et al., 2015).
ROS, including hydrogen peroxide
(H2O2) and superoxide (O2
d) and hy-
droxyl (HOd) free radicals, are mainlyproduced during oxygen-consuming
metabolic reactions that occur in peroxi-
somes, the endoplasmic reticulum, and
the mitochondria, which is their major
source. Moderate ROS levels have
been shown to support cell proliferation
and migration and activate stress-
induced signaling pathways involved in
cell survival, therefore contributing to tu-
mor development (Gorrini et al., 2013).
Accordingly, the use of antioxidants to
quench oxidative stress has been postu-
lated as a preventive and therapeutic
anticancer strategy. Thus, large-scale
clinical trials using antioxidant supple-
mentation have been conducted, though
they failed to benefit patients and even
increased cancer incidence (Sayin
et al., 2014). Considering the relevance
of oxidative stress in cancer develop-
ment, why have many clinical trialsbased on antioxidant supplementation
not shown therapeutic efficacy? One
possibility is that excessive ROS accu-
mulation promotes severe cellular dam-
age and triggers apoptosis, which makes
a tight redox regulation essential for the
cell. Indeed, cancer cells depend on an
increased antioxidant capacity, which
keeps ROS levels higher than in normal
cells, but below a critical threshold able
to maintain their viability. It has been
observed that the same stimuli that pro-
mote oxidative stress, such as detach-
ment from the cell matrix, also increase
the selective pressure on cells to adapt
by building up a powerful antioxidant
response (Gorrini et al., 2013).
The study performed by Piskounova
et al. supports that notion. To identify
the mechanistic differences in the meta-
static activity of several melanomas, the
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Figure 1. Is the Cancer Cell Metabolic Response to Oxidative Stress What Allows
Metastasis?
(A) Piskounova et al. (2015) provide evidence that successful metastatic cells have undergone several
reversible metabolic changes that allow them to buffer oxidative stress, including upregulation in meta-
bolic pathways that produce antioxidant power.
(B) Melanoma cells that have detached from established subcutaneous tumors have higher ROS levels
when they are in the bloodstream and at distant metastatic sites.
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Previewsauthors performed a metabolomics anal-
ysis on patient-derived melanoma xeno-
grafts and the metastases that they
generated. Cancer cells isolated from
blood and from metastatic sites dis-
played higher levels of cytoplasmic and
mitochondrial-derived ROS than those
from the primary subcutaneous tumors
(Figure 1A). Paradoxically, treatment
with the antioxidant N-acetyl-cysteine
(NAC) increased the presence of circu-
lating cancer cells and metastatic
burden, indicating that cellular oxidativestress limits metastasis in vivo. More-
over, metastatic tumors showed a
reversible increase in the overall produc-
tion of the endogenous antioxidants
glutathione and NADPH, which was
linked to a higher folate pathway activity,
indicating that tumor cells adopt adap-
tive measures to neutralize oxidative
stress. Indeed, blocking the folate
pathway either by genetically downregu-
lating the expression of enzymes of
this pathway or by pharmacologically
inhibiting it using methotrexate de-Cell Metabolism 22,creased melanoma metastasis in mice
(Figure 1A) (Piskounova et al., 2015). In
conclusion, the authors show that effi-
cient spread and metastatic seeding of
melanoma cells not only depends on
their high ROS production but also on
their ability to withstand the cellular
oxidative stress they experience, as
they travel through the bloodstream
and initiate new metastatic lesions
(Figure 1B).
Other recent studies have also demon-
strated that administration of broad exog-
enous antioxidants provides cancer cells
with proliferation and survival signals
that allow metastasis (Le Gal et al.,
2015). Thus, the use of pro-oxidant drugs
and/or chemical inhibitors of the antioxi-
dant response would be attractive ap-
proaches for cancer treatment. These
two complementary strategies would
exceed the cellular antioxidant capacity
of cancer cells, preventing metastases.
Interestingly, many anticancer agents
currently used in clinical practice directly
or indirectly act as pro-oxidants, though
with significant toxicity.
It is also important to note that, in an
apparent contradiction to the results of
Piskounova et al., several other reports
have shown that inhibition of mitochon-
drial oxidative stress prevents metastasis
(Goh et al., 2011; Porporato et al., 2014).
These studies point to a different expla-
nation: only a small proportion of antiox-
idants in vivo are actually located in the
mitochondria, the main source of ROS.
The mitochondrial antioxidant pool is
actually distinct and separated from
that of the cytoplasm (Costa et al.,
2003), with mitochondria having their
own antioxidant enzymes, such as gluta-
thione reductases, peroxidases, and
NADPH-generating sources. Thus, one
reason for the failure of dietary antioxi-
dants could be that they are not able to
target and diminish the ROS generated
and localized in the mitochondria.
Indeed, the use of mitochondrial antioxi-
dants effectively reduces tumorigenesis
in mouse models (Nazarewicz et al.,
2013; Porporato et al., 2014; Weinberg
et al., 2010).
Given that natural selection of a
phenotype associated with mitochon-
drial superoxide production directly pro-
motes cell migration, invasion, and
metastasis in vivo, specific targeting of
mitochondrial ROS may result in aDecember 1, 2015 ª2015 Elsevier Inc. 957
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Both targeting of the mitochondrial
electron transport chain and the phar-
macological scavenging of mitochon-
drial superoxide prevent metastatic
dissemination from primary orthotopic
tumors in mice (Porporato et al.,
2014). Mitochondrial-generated oxida-
tive stress can also be attenuated with
clinically relevant health benefits by
increasing the levels of mitochondrial
antioxidant enzymes or by ectopically
expressing antioxidant enzymes within
the mitochondria. For instance, overex-
pression of mitochondrial-localized
catalase in vivo increases lifespan, and
transgenic expression of mitochondrial
catalase in the MMTV-PyMT mammary
cancer model reduces ROS-driven pri-
mary tumor invasiveness and markedly
suppresses lung metastases (Goh
et al., 2011; Schriner et al., 2005).
Therefore, strategies that effectively
eliminate ROS specifically within the
mitochondrial compartment by mito-
chondrial-specific antioxidant adminis-958 Cell Metabolism 22, December 1, 2015 ªtration might still represent a therapeu-
tic approach for metastatic cancer.
Despite intensive research, current
antioxidant strategies are not clinically
effective, suggesting that our under-
standing of this field is limited and the
exact nature of the impact of oxidative
stress on cancer metastasis requires
further investigation. The role of ROS
and antioxidants depending on their
origin in cancer progression and metas-
tasis needs to be fully characterized in
future studies to identify new therapeutic
targets.REFERENCES
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In adipose tissue, there is a delicate balance between storing and expending energy. In this issue, Shinoda
et al. (2015) use phosphoproteomics to identify casein kinase 2 (CK2) as a suppressor of brown adipocyte
formation, providing insights into how adipose tissue regulates its composition of white versus brown
adipocytes.On the one hand, it is well known that pro-
longed exposure to cold will induce
‘‘browning,’’ an increase in the number
of beige adipocytes (also known as brite;
a type of brown adipocyte interspersed
among white adipocytes in predomi-
nantly white adipose depots), while on
the other hand high-fat diet feeding or
exposure to thermoneutrality (a tempera-
ture of about 28C–30C, at which micedo not need to activate brown fat for
heat production) will have the opposite
effect, with less browning and more of a
homogenous white phenotype of adipose
depots (Cinti, 2005). Thus, the adipose
tissue is a dynamic tissue that responds
and adapts to physiological stimuli such
as nutritional status and changes in
ambient temperature. Using in vivo ge-
netic lineage tracing techniques, Leeet al. (2012) identified a PDGFRa+,
CD34+, and Sca1+ precursor cell with
the capacity to proliferate and differen-
tiate into both brown and white adipo-
cytes. Such bipotent precursors devel-
oped into brown adipocytes when mice
were treated with a b3-agonist (mimicking
cold exposure) and into white adipocytes
when mice were high-fat fed. This impor-
tant finding helps explain the dynamics of
